ABOS - NASDAQ
Acumen Pharmaceuticals, Inc.
$2.29
-0.65%Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
At a Glance
Live Snapshotabos
Total Assets
Last Annual Value
122.83M
3-Year CAGR
-15%
5-Year CAGR
23%
10-Year CAGR
33%
Acumen Pharmaceuticals, Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | 122.83M | -26.6% | -11.8% | N/A | |
 Seer, Inc. NASDAQ:SEER | 296.08M | -12.1% | -11.3% | N/A | |
 Actuate Therapeutics Inc NASDAQ:ACTU | 14.04M | 67.3% | N/A | N/A | |
 C4 Therapeutics, Inc. NASDAQ:CCCC | 359.07M | -1.6% | -6.7% | N/A | |
 PepGen Inc. NASDAQ:PEPG | 173.91M | 6.7% | 3.9% | N/A | |
 Instil Bio, Inc. NASDAQ:TIL | 203.52M | -14.5% | -19.7% | N/A | |
 Tevogen Bio Holdings Inc. NASDAQ:TVGN | 3.46M | -14.3% | -14.7% | N/A | |
 Agenus Inc. NASDAQ:AGEN | 226.80M | -10.3% | -13.4% | 3.7% | |
 VistaGen Therapeutics, Inc. NASDAQ:VTGN | 84.34M | 58.7% | -4.9% | 56.0% | |
 Alector, Inc. NASDAQ:ALEC | 293.24M | -22.2% | -18.5% | 18.4% | |
 Inovio Pharmaceuticals, Inc. NASDAQ:INO | 74.31M | -24.2% | -31.6% | -8.1% |
Acumen Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your ABOS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.